CDK4 inhibitors and apoptosis: A novel mechanism requiring nucleolar targeting of RelA

Cell Cycle

Volumn 6, Issue 11, 2007, Pages 1293-1297

  Thoms, Hazel C ^a   Dunlop, Malcolm G ^a   Stark, Lesley A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; NF B; Nucleolus; RelA (p65); Repression

Indexed keywords

2 BROMO 12,13 DIHYDRO INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7 DIONE; 7 HYDROXYSTAUROSPORINE; ACETYLSALICYLIC ACID; APHIDICOLIN; CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; DEMECOLCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIMOSINE; ROSCOVITINE; RUGOSIN E; SURVIVIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; 2 BROMO 12,13 DIHYDRO 5 INDOLO(2,3 A)PYRROLO(3,4 C)CARBAZOLE 5,7(6H) DIONE; 2-BROMO-12,13-DIHYDRO-5-INDOLO(2,3-A)PYRROLO(3,4-C)CARBAZOLE-5,7(6H)-DIONE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 (5 PIPERAZIN 1 YLPYRIDIN 2 YLAMINO) 8H PYRIDO(2,3 D)PYRIMIDIN 7 ONE; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; CDK4 PROTEIN, HUMAN; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLINE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RELA PROTEIN, HUMAN;

APOPTOSIS; CANCER CELL; CELL CYCLE ARREST; CELL VIABILITY; COLON CANCER; DRUG INHIBITION; DRUG MECHANISM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; ADENOCARCINOMA; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL CYCLE; CHEMISTRY; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; NUCLEOLUS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBAZOLES; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEOLUS; CLINICAL TRIALS, PHASE I; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MICE; MODELS, BIOLOGICAL; NF-KAPPA B; PIPERAZINES; PROTEIN TRANSPORT; PYRIDINES; TRANSCRIPTION FACTOR RELA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547684724     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.11.4312     Document Type: Review

References (46)

1. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770-83.
2. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 1995; 55:6200-9.
3. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378:F115-77.
4. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001; 413:86-91.
5. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991; 350:512-5.
6. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002; 1:226-31.
7. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003; 63:7056-61.
8. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, Hardisson D, Sarrio D, Prat J, Cigudosa JC, Matias-Guiu X, Palacios J. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 2003; 22:6115-8.
9. Zhou P, Jiang W, Zhang YJ, Kahn SM, Schieren I, Santella RM, Weinstein IB. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995; 11:571-80.
10. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR, Weinstein IB. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997; 57:1569-74.
11. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 1999; 59:4876-81.
12. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007; 98:629-35.
13. Schreiber M, Muller WJ, Singh G, Graham FL. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 1999; 18:1663-76.
14. Ferrer JL, Dupuy J, Borel F, Jacquamet L, Noel JP, Dulic V. Structural basis for the modulation of CDK-dependent/independent activity of cyclin D1. Cell Cycle 2006; 5:2760-8.
15. Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst 2001; 93:436-46.
16. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38.
17. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006; 66:7661-7.
18. VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin III J, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL. Pyrido[2,3-d]pyrimidin-7- ones as specific inhibitors of cyclin-dependent kinase 4. J Med Chem 2005; 48:2371-87.
19. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48:2388-406.
20. Retzer-Lidl M, Schmid RM, Schneider G. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer 2007.
21. Stark LA, Din FV, Zwacka RM, Dunlop MG. Aspirin-induced activation of the NF-kappaB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 2001; 15(7):1273-515:1273-5.
22. Stark LA, Dunlop MG. Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis. Mol Cell Biol 2005; 25:5985-6004.
23. Thoms HC, Dunlop MG, Stark LA. p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res 2007; 67:1660-9.
24. Zhu G, Conner SE, Zhou X, Shih C, Li T, Anderson BD, Brooks HB, Campbell RM, Considine E, Dempsey JA, Faul MM, Ogg C, Patel B, Schultz RM, Spencer CD, Teicher B, Watkins SA. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem 2003; 46:2027-30.
25. Mistry P, Deacon K, Mistry S, Blank J, Patel R. NF-kappaB promotes survival during mitotic cell cycle arrest. J Biol Chem 2004; 279:1482-90.
26. Juan G, Cordon-Cardo C. Intranuclear compartmentalization of cyclin E during the cell cycle: Disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer. Cancer Res 2001; 61:1220-6.
27. David-Pfeuty T, Nouvian-Dooghe Y. Human p14(Arf): An exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function. Oncogene 2002; 21:6779-90.
28. Brady SN, Yu Y, Maggi Jr LB, Weber JD. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol 2004; 24:9327-38.
29. Kubens BS, Niggemann B, Zanker KS. Prevention of entrance into G2 cell cycle phase by mimosine decreases locomotion of cells from the tumor cell line SW480. Cancer Lett 2001; 162(Suppl):S39-S47.
30. Jin Z, Dicker DT, El Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002; 1:82-9.
31. Gladden AB, Diehl JA. Location, location, location: The role of cyclin D1 nuclear localization in cancer. J Cell Biochem 2005; 96:906-13.
32. Chen M, Capps C, Willerson JT, Zoldhelyi P. E2F-1 regulates nuclear factor-kappaB activity and cell adhesion: Potential antiinflammatory activity of the transcription factor E2F-1. Circulation 2002; 106:2707-13.
33. Takemura M, Ohoka F, Perpelescu M, Ogawa M, Matsushita H, Takaba T, Akiyama T, Wmekawa H, Furuichi Y, Cook PR, Yoshida S. Phosphorylation-dependent migration of retinoblastoma protein into the nucleolus triggered by binding to nucleophosmin/B23. Exp Cell Res 2002; 276:233-41.
34. Szebeni A, Hingorani K, Negi S, Olson MO. Role of protein kinase CK2 phosphorylation in the molecular chaperone activity of nucleolar protein b23. J Biol Chem 2003; 278:9107-15.
35. Kato Jr T, Delhase M, Hoffmann A, Karin M. CK2 is a C-Terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol Cell 2003; 12:829-39.
36. Li J, Joo SH, Tsai MD. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4. Biochemistry 2003; 42:13476-83.
37. Aggarwal BB. Nuclear factor-kappaB: The enemy within. Cancer Cell 2004; 6:203-8.
38. Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, Fujii M, Hatano M, Tokuhisa T, Mori N. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 2005; 115:967-74.
39. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54.
40. Kuo PL, Hsu YL, Lin TC, Tzeng WS, Chen YY, Lin CC. Rugosin E, an ellagitannin, inhibits MDA-MB-231 human breast cancer cell proliferation and induces apoptosis by inhibiting nuclear factor-kappaB signaling pathway. Cancer Lett 2006; 248:280-91.
41. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1996; 219:778-83.
42. Bhonde MR, Hanski ML, Magrini R, Moorthy D, Muller A, Sausville EA, Kohno K, Wiegand P, Daniel PT, Zeitz M, Hanski C. The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. Oncogene 2005; 24:148-56.
43. Tsukahara T, Kannagi M, Ohashi T, Kato H, Arai M, Nunez G, Iwanaga Y, Yamamoto N, Ohtani K, Nakamura M, Fujii M. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol 1999; 73:7981-7.
44. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 2004; 13:853-65.
45. DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, Lovey A, Cehn Y, Qian H, Hamid R, Xiang Q, Tovar C, Blain R, Nevins T, Higgins B, Luistro L, Kolinsky K, Felix B, Hussain S, Heimbrook D. In vitro and in vivo activity of R547: A potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006; 5:2644-58.
46. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61:4301-5.